Soleno Therapeutics (NASDAQ:SLNO) Receives Peer Perform Rating from Wolfe Research

Wolfe Research reissued their peer perform rating on shares of Soleno Therapeutics (NASDAQ:SLNO) in a report released on Tuesday morning,Benzinga reports.

Other analysts have also issued research reports about the company. Wells Fargo & Company decreased their price objective on Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating on the stock in a research note on Friday, February 27th. Lifesci Capital lowered shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday. Robert W. Baird set a $107.00 target price on shares of Soleno Therapeutics in a research report on Tuesday, January 13th. TD Cowen decreased their target price on shares of Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Soleno Therapeutics in a research report on Thursday, January 22nd. Seven analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $93.90.

Soleno Therapeutics Stock Up 0.2%

SLNO opened at $52.35 on Tuesday. The company has a quick ratio of 5.55, a current ratio of 5.80 and a debt-to-equity ratio of 0.11. The firm has a market cap of $2.70 billion, a P/E ratio of 227.62 and a beta of -2.81. Soleno Therapeutics has a 52 week low of $29.43 and a 52 week high of $90.32. The business’s fifty day simple moving average is $38.17 and its 200 day simple moving average is $47.80.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.16. The company had revenue of $91.73 million for the quarter, compared to analyst estimates of $88.55 million. As a group, equities research analysts anticipate that Soleno Therapeutics will post -3.72 EPS for the current fiscal year.

Institutional Trading of Soleno Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Janus Henderson Group PLC boosted its stake in Soleno Therapeutics by 18.5% in the 4th quarter. Janus Henderson Group PLC now owns 7,178,354 shares of the company’s stock worth $332,302,000 after buying an additional 1,122,015 shares during the last quarter. Wellington Management Group LLP boosted its stake in Soleno Therapeutics by 43.7% in the 4th quarter. Wellington Management Group LLP now owns 3,322,799 shares of the company’s stock worth $153,846,000 after buying an additional 1,010,704 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Soleno Therapeutics by 9.0% in the 4th quarter. Vanguard Group Inc. now owns 3,060,361 shares of the company’s stock valued at $141,695,000 after purchasing an additional 253,212 shares during the last quarter. Avoro Capital Advisors LLC boosted its holdings in shares of Soleno Therapeutics by 12.5% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,900,000 shares of the company’s stock valued at $134,270,000 after purchasing an additional 322,223 shares during the last quarter. Finally, State Street Corp boosted its holdings in shares of Soleno Therapeutics by 21.9% in the 4th quarter. State Street Corp now owns 2,649,626 shares of the company’s stock valued at $122,678,000 after purchasing an additional 476,590 shares during the last quarter. 97.42% of the stock is owned by institutional investors and hedge funds.

Soleno Therapeutics News Roundup

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Neurocrine agreed to acquire Soleno for $53.00 per share in cash (about $2.9B), giving SLNO shareholders an immediate cash premium and a clear near‑term exit/liquidity event. Read More.
• Neutral Sentiment: Some research shops have set conservative near‑term views (reaffirmations / “peer perform” ratings) as the deal closes and integration risk becomes the focus; these are neutral for deal economics but can mute momentum. Read More.
• Negative Sentiment: Soleno voluntarily withdrew its European marketing application for VYKAT™ XR, citing the acquirer’s plan to sharpen focus on the U.S. market — this reduces near‑term international upside and could lower future revenue projections for the combined company. Read More.
• Negative Sentiment: Dozens of law firms have filed or are soliciting plaintiffs in securities class actions tied to Soleno’s 2025 DCCR/VYKAT XR trial/launch setbacks; litigation risk could create damages exposure, distraction and potential deal complications. Read More.
• Negative Sentiment: Multiple firms are investigating whether the $53/share deal is fair to public shareholders and several analysts have downgraded or cut targets — these actions can pressure the stock and may prompt negotiation or litigation over price. Read More.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.